Effects of Investigational Pulmonary Fibrosis Drug Request More Information Trial Objective Researchers want to know if an investigational drug called BKS-986278 will help prevent or slow down the progression of pulmonary fibrosis, which is also known as lung fibrosis or interstitial lung disease. Researchers are studying the safety and efficacy of the drug and gathering information on the drug levels of this medication. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate People who have been diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive interstitial lung disease (PF-ILD) within the last seven years may be eligible for this study. Age: IPF patients: 40+ PF-ILD patients: 21+ Gender: Any Gender Estimated Time Commitment 34 weeks If you complete the entire study, you will be asked to make up to 10 visits to the clinic and have one phone call follow-up. × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Kristina Eliopoulos 303.270.2622 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Bristol-Myers Squibb Principal Investigators Michael Mohning, MD + × Michael Mohning, MD Assistant Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine Interstitial Lung Disease Program View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Co-Investigators Jeffrey Swigris, DO, MS + × Jeffrey Swigris, DO, MS Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Joshua Solomon, MD + × Joshua Solomon, MD Director, Interstitial Lung Disease Program Associate Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine Section of Critical Care Medicine View Full Profile Patient Rating 4.7 out of 5 stars Make an Appoinment Matthew Koslow, MD + × Matthew Koslow, MD Assistant Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine View Full Profile Patient Rating 4.6 out of 5 stars Make an Appoinment Rebecca Keith, MD + × Rebecca Keith, MD Associate Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine Interstitial Lung Disease Program Autoimmune Lung Center View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Zulma Yunt, MD + × Zulma Yunt, MD Assistant Professor of Medicine Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Researchers want to know if an investigational drug called BKS-986278 will help prevent or slow down the progression of pulmonary fibrosis, which is also known as lung fibrosis or interstitial lung disease. Researchers are studying the safety and efficacy of the drug and gathering information on the drug levels of this medication.